GYNECOLOGIC ONCOLOGY GROUP

妇科肿瘤组

• 批准号: 6937194
• 负责人: Philip J. DiSaia
• 金额: $ 241.78万
• 依托单位: GYNECOLOGIC ONCOLOGY GROUP
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-01 至 2007-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6937194
• 关键词: cancer prevention; clinical research; clinical trial phase III; clinical trials; cooperative study; female; female reproductive system neoplasm; human subject; human therapy evaluation; interdisciplinary collaboration; medical outreach /case finding; neoplasm /cancer therapy; patient oriented research

DESCRIPTION (provided by applicant): This application is for the Gynecologic Oncology Group (GOG) CCOP Research Base. The Gynecologic Oncology Group is the premier clinical trial group in treatment of gynecologic cancers and has developed an active cancer prevention and control program. The composition of the Gynecologic Oncology Group includes gynecologic oncologists, medical oncologists, radiation oncologists, pathologists, nurse oncologists, biostatisticians, laboratory scientists, behavioral scientists, epidemiologists and other disciplines. The GOG is strengthened by an affiliate network of community-based investigative teams led by gynecologic oncologists. This network consists of small university and/or large community hospitals and should serve as a significant supplement in the prevention program by augmenting contributions from existing and new CCOP organizations in providing enhanced opportunities for recruitment and enrollment of patients into cancer prevention trials. The CCOP institutions formed along the lines of typical multi-site medical oncology cooperative groups will find opportunities to enter patients into treatment and prevention trials developed by the GOG. However, many of the future prevention studies will require access to patient groups previously not seen in CCOP institutions. As they adjust to these new challenges, the affiliate network already in place in the GOG will provide support and leadership in making the prevention program successful. In previous experiences as a Research Base, the GOG's CCOP institutions have met treatment goals. The GOG lost its Research Base status due to failure of the CCOPs to meet prevention goals. The combination of CCOP and Prevention Member Gynecologic Oncology Affiliate institutions should correct that previous deficit. Patient Accrual: Under the previous Research Base funding, patient accrual to treatment trials was satisfactory for each year of the grant - 1997 through 1999. In terms of prevention, the CCOP institutions did not meet the standards provided. While that experience showed that the requirements of the GOG in terms of cancer prevention studies may be different from those developed by other Research Bases, it also showed that there were CCOP organizations that could meet the challenge. The time requirement for adjustment was longer than anticipated. However, there is a provision in the current RFA allowing the designation of members of the cooperative clinical trial organization as Prevention Members.

描述（由申请人提供）：本申请是妇科肿瘤组（GOG）CCOP研究基地。妇科肿瘤组是治疗妇科癌症的首要临床试验组，并制定了积极的癌症预防和控制计划。妇科肿瘤组的组成包括妇科肿瘤学家、内科肿瘤学家、放射肿瘤学家、病理学家、肿瘤护士、生物统计学家、实验室科学家、行为科学家、流行病学家和其他学科。由妇科肿瘤学家领导的社区调查小组的附属网络加强了GOG。该网络由小型大学和/或大型社区医院组成，应作为预防计划的重要补充，通过增加现有和新的CCOP组织的贡献，为癌症预防试验招募和招募患者提供更多机会。CCOP机构按照典型的多地点医学肿瘤学合作小组的路线形成沿着，将寻找机会让患者参加GOG开发的治疗和预防试验。然而，许多未来的预防研究将需要访问以前没有看到在CCOP机构的患者群体。随着他们适应这些新的挑战，GOG已经建立的附属网络将提供支持和领导，使预防方案取得成功。在以往作为研究基地的经验中，圭亚那政府的CCOP机构达到了治疗目标。由于CCOP未能实现预防目标，圭亚那政府失去了研究基地的地位。CCOP和预防成员妇科肿瘤附属机构的组合应该纠正以前的缺陷。患者累积：在以前的研究基地资助下，1997年至1999年的每一年，患者对治疗试验的反应都是令人满意的。在预防方面，CCOP机构没有达到规定的标准。虽然这一经验表明，希腊政府在癌症预防研究方面的要求可能与其他研究基地的要求不同，但它也表明，有一些CCOP组织能够迎接这一挑战。调整所需的时间比预期的要长。然而，现行RFA中有一项条款允许将合作临床试验组织的成员指定为预防成员。